As 2024 comes to a close, we here at Ophthalmology Times and the greater Eye Care Network would like to thank you–the reader.

Deepinder Dhaliwal, MD, LAc, explores advancements in managing Fuchs endothelial corneal dystrophy, highlighting Descemet ...

Deepinder Dhaliwal, MD, LAc, discusses longterm outcomes of Descemet Stripping Only (DSO) for Fuchs dystrophy at NYU's ...

A Helsinki University Hospital study found diabetes, glycemic control, or insulin therapy did not significantly affect ...

The NYU Grossman School of Medicine launches a Journal Club series with Ophthalmology Times, featuring expert faculty ...

Glaukos submitted an NDA for Epioxa, a novel corneal cross-linking therapy for keratoconus, to the US FDA. Epioxa's Phase 3 ...

Investigators conducted a retrospective clinical audit to determine why patients do not adhere to the guidelines among about 9,000 patients in a practice.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for. This series features experts in ophthalmology sharing their ...

Faricimab shows superior durability and efficacy in treating neovascular AMD, DME, and CRVO, allowing for extended treatment intervals and reduced burden. In DME cases, faricimab outperformed ...

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.